About Vicarious Surgical Inc. WT
https://www.vicarioussurgical.comVicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
CEO
Adam David Sachs
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Devices
Sector Healthcare
Went public N/A
Method of going public SPAC
Full time employees 123
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $14.16 M
52w High $0.02
52w Low $0.01
P/E 0
Volume 138.82K
Outstanding Shares 1.73B
About Vicarious Surgical Inc. WT
https://www.vicarioussurgical.comVicarious Surgical Inc. engages in developing and selling single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. It offers Vicarious System, a single-incision surgical robot for ventral hernia repair. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $11.15M ▼ | $-11.06M ▲ | 0% | $-1.86 ▲ | $-10.71M ▲ |
| Q2-2025 | $0 | $13.52M ▼ | $-13.21M ▲ | 0% | $-2.23 ▲ | $-13.11M ▲ |
| Q1-2025 | $0 | $15.75M ▲ | $-15.39M ▼ | 0% | $-2.6 ▼ | $-15.38M ▼ |
| Q4-2024 | $0 | $14.44M ▼ | $-13.93M ▲ | 0% | $-2.36 ▲ | $-13.38M ▲ |
| Q3-2024 | $0 | $17.75M | $-17.09M | 0% | $-2.9 | $-16.58M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $13.41M ▼ | $29.35M ▼ | $15.26M ▼ | $14.09M ▼ |
| Q2-2025 | $23.96M ▼ | $40.89M ▼ | $17.83M ▼ | $23.06M ▼ |
| Q1-2025 | $37.36M ▼ | $55.05M ▼ | $20.98M ▼ | $34.08M ▼ |
| Q4-2024 | $49.1M ▼ | $67.72M ▼ | $21.02M ▼ | $46.7M ▼ |
| Q3-2024 | $60.86M | $80.62M | $22.73M | $57.88M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.06M ▲ | $-10.42M ▲ | $9.65M ▼ | $25.91K ▲ | $-746K ▼ | $-10.54M ▲ |
| Q2-2025 | $-13.21M ▲ | $-13.49M ▼ | $14.79M ▲ | $23.93K ▲ | $1.31M ▲ | $-13.49M ▼ |
| Q1-2025 | $-15.39M ▼ | $-11.77M ▲ | $4.61M ▼ | $17K ▲ | $-7.14M ▼ | $-11.77M ▲ |
| Q4-2024 | $-13.93M ▲ | $-11.79M ▲ | $14.45M ▲ | $6K ▲ | $2.67M ▲ | $-11.97M ▲ |
| Q3-2024 | $-17.09M | $-12.69M | $-492K | $0 | $-13.18M | $-12.67M |
CEO
Adam David Sachs
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Devices
Sector Healthcare
Went public N/A
Method of going public SPAC
Full time employees 123
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0